Mutations in members of the EGFR pathway, including KRAS, are of particular interest as the use of EGFR inhibitors such as gefitinib has been described for urachal carcinoma recently (Collazo‐Lorduy et al., 2016; Singh et al., 2016; Sirintrapun et al., 2014). This evidence concerns the gene KRAS and bladder urachal carcinoma.